Verrica Pharmaceuticals Settles Litigation with Dormer Labs Over Cantharidin Products

Verrica Pharmaceuticals Inc

WEST CHESTER, PAVerrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced the settlement of a legal dispute with Dormer Laboratories, Inc. this week. As part of the agreement, Dormer Labs will stop selling all cantharidin-containing products in the United States, including their Cantharone (Liquid) and Cantharone Plus brands.

“We are pleased to announce the expeditious settlement with Dormer Labs, which Verrica believes was the largest supplier of non-FDA approved cantharidin-containing products into the U.S. market,” said Ted White, Verrica’s President and Chief Executive Officer. “This settlement should send a clear message that Verrica will remain vigilant in its efforts to identify and stop any drug manufacturer or distributor that seeks to market, sell or distribute non-FDA approved cantharidin in the United States. We believe that this settlement will result in greater patient usage of the FDA-approved YCANTH.”

The company emphasized the importance of adhering to FDA guidelines for patient safety. Non-approved cantharidin products pose risks due to their instability and inconsistent concentrations. Verrica’s YCANTH is the only FDA-approved cantharidin therapy for treating molluscum contagiosum, a skin infection.

The settlement marks a significant step in Verrica’s ongoing efforts to ensure that only safe and effective treatments are available to patients. By removing non-FDA approved products from the market, Verrica aims to increase reliance on YCANTH, which has been deemed safe by regulatory authorities. The company remains committed to monitoring and addressing any violations of FDA standards related to cantharidin products.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.